Axonics Modulation Technologies (NSDQ:AXNX) announced positive top-line results from a pivotal study of its novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction.
The clinical study demonstrated that patients implanted with the Axonics r-SNM system experienced clinically meaningful and statistically significant improvements in urinary urgency incontinence (UUI) symptoms and quality of life, according to the Irvine, Calif.-based company. The study also met all secondary endpoints, and no serious device-related adverse events were reported.
Get the full story on our sister site, Medical Design & Outsourcing.
The post Axonics Modulation touts results of sacral neuromodulation study appeared first on MassDevice.
from MassDevice https://ift.tt/2Vc97hU
Cap comentari:
Publica un comentari a l'entrada